MedTrace Logo

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

NCT00120939 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2009-04-03

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.

Conditions

  • Breast Neoplasms
  • Ovarian Neoplasms
  • Prostatic Neoplasms
  • Lung Neoplasms
  • Gastrointestinal Neoplasms

Interventions

DRUG

Motexafin Gadolinium

Sponsors & Collaborators

  • Pharmacyclics LLC.

    lead INDUSTRY

Principal Investigators

  • Gurkamal Chatta, MD · University of Pittsburgh Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00120939 on ClinicalTrials.gov